tailieunhanh - Báo cáo y học: "Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthriti"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. | Rudwaleit et al. Arthritis Research Therapy 2010 12 R43 http content 12 2 R43 RESEARCH ARTICLE Open Access Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis K lsrtlrs Pl ir kA aldCPaccal r-l A irlcir jcirrci2 K srUrss kVrsrs3 CrAai A ICsrx 3 A r rsr i4 5 It ló irsrsdr3 Martin Rudwaleit rascal Claudepiene Manina kioii Sonja Kaiy Robert Wong Hdiuiiui isupper Abstract Introduction The purpose of this study was to investigate the effectiveness of adalimumab in enthesitis and peripheral arthritis in patients with ankylosing spondylitis AS . Methods Adults with active AS Bath ankylosing spondylitis disease activity index BASDAI 4 received adalimumab 40 mg every other week with standard antirheumatic therapies in a 12-week open-label study. Effectiveness in enthesitis was assessed using the Maastricht ankylosing spondylitis enthesitis score MASES 0-13 and by examining the plantar fascia in patients with enthesitis 1 inflamed enthesis at baseline effectiveness in peripheral arthritis was evaluated using tender and swollen joint counts TJC 0-46 SJC 0-44 in patients with peripheral arthritis 1 swollen joint at baseline. Overall effectiveness measures included Assessment of SpondyloArthritis International Society 20 response ASAS20 . Results Of 1 250 patients enrolled 686 had enthesitis and 281 had peripheral arthritis. In 667 patients with MASES 1 at baseline the median MASES was reduced from 5 at baseline to 1 at week 12. At week 12 inflammation of the plantar fascia ceased in 122 of 173 patients with inflammation at baseline. The median TJC in 281 patients with SJC 1 at baseline was reduced from 5 at baseline to 1 at week 12 the median SJC improved from 2 to 0. ASAS20 responses were achieved by of 457 patients with no enthesitis and no arthritis of 512 patients with only enthesitis of 107 patients with only arthritis and of 174 patients with both. .